CN110881663A - Complex microbial inoculant for liver protection - Google Patents
Complex microbial inoculant for liver protection Download PDFInfo
- Publication number
- CN110881663A CN110881663A CN201911418378.2A CN201911418378A CN110881663A CN 110881663 A CN110881663 A CN 110881663A CN 201911418378 A CN201911418378 A CN 201911418378A CN 110881663 A CN110881663 A CN 110881663A
- Authority
- CN
- China
- Prior art keywords
- complex microbial
- lactobacillus rhamnosus
- liver
- microbial inoculum
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 21
- 230000000813 microbial effect Effects 0.000 title claims description 7
- 239000002054 inoculum Substances 0.000 title claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 24
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims abstract description 17
- 229920002307 Dextran Polymers 0.000 claims abstract description 14
- 239000002068 microbial inoculum Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 235000021107 fermented food Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 230000000694 effects Effects 0.000 description 13
- 244000183278 Nephelium litchi Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000002075 anti-alcohol Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- KJEFZXSIQKASDI-YFHVBOCQSA-N (2S)-2-methyltetradecanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@@H](C)CCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 KJEFZXSIQKASDI-YFHVBOCQSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a complex microbial inoculum for liver protection, which comprises the following components: leuconostoc mesenteroides dextran subspecies LZ1 and other acceptable food or pharmaceutical excipients. Further preferably, the complex microbial inoculum also comprises a Lactobacillus rhamnosus (Lactobacillus rhamnosus) strain CGMCC No. 3002. The compound microbial inoculum can be prepared into oral liquid, freeze-dried powder, capsules and the like.
Description
Technical Field
The invention relates to a complex microbial inoculum for liver protection, belonging to the technical field of microorganisms.
Background
China has a long-standing wine culture, however, it is well known that less than 10% of alcohol in the body can be directly discharged and turned into body through urine, exuberance, sweat, saliva and the like, and 90% of hexanol needs to be metabolized in the liver. In recent years, wine and alcoholism are increasing, ethanol can cause damage to human viscera to different degrees, and the liver is the first thing. Alcohol can damage the symptom structure of liver cells, reduce the physiological function of microtubules, damage mitochondria and the like, promote the proliferation of hepatic interstitial and fibroid tissues, influence energy metabolism and generate excessive free radicals, increase the risk of liver damage and cause inflammatory cell infiltration in the liver; in addition, the metabolism of alcohol by microsomal oxidase in liver interferes with intracellular redox reaction, so that the metabolism of fat, carbohydrate and protein in liver cells is disturbed, fat accumulation in liver is caused, and diseases such as alcoholic hepatitis and fatty liver are caused.
Current studies on the effects of diet and chocolate on ethanol metabolism indicate that various substances can help protect the liver from alcohol: such as water extracts of thyme and ginger, are effective in reducing the level of pro-oxidant substances in the liver and increasing the level of antioxidant substances. And the content of ethanol in the blood of the model rabbit can be obviously reduced if the rabbit is like the crystal sugar vinegar.
The invention aims to provide a composite microbial inoculum for liver protection, which can be planted in gastrointestinal tracts efficiently and exert excellent anti-alcohol effect, thereby achieving the aim of protecting the liver.
Disclosure of Invention
The invention aims to provide a composite microbial inoculum for liver protection, which can be planted in gastrointestinal tracts efficiently and exert excellent anti-alcohol effect, thereby achieving the aim of protecting the liver.
Southern agricultural Journal of Southern agricultural 2019, 50 (1): 137-143 and screening, identifying and fermenting effect analysis of litchi endophytic lactic acid bacteria disclose a leuconostoc mesenteroides glucan subspecies LZ1, and the leuconostoc mesenteroides glucan subspecies LZ1 can be found to grow well in litchi juice, and the fermented litchi juice not only preserves and optimizes the nutrition and taste of the juice, but also adds the health-care function of probiotics. The strain is derived from litchi serving as a traditional food, and the safety is very guaranteed.
The company team further researches the strain to find that the strain has a certain anti-inebriation effect, but the in vitro anti-inebriation capability is good, and the in vivo anti-inebriation capability is weak.
In addition, the prior art further discloses a Lactobacillus rhamnosus (Lactobacillus rhamnosus) strain CGMCC No.3002, wherein Lactobacillus rhamnosus surface protein is expressed in the strain, the adhesion capability of the Lactobacillus rhamnosus SLP in human intestinal tracts is greatly enhanced, and the positive efficacy of the Lactobacillus rhamnosus in human digestive tracts can be effectively enhanced. In the research and practice processes of the invention, the team discovers that the combination of oral leuconostoc mesenteroides glucan subspecies LZ1 and Lactobacillus rhamnosus (Lactobacillus rhamnosus) strain CGMCC No.3002 can effectively enhance the in-vivo anti-alcohol effect and achieve the good effect of protecting the liver.
The technical problem to be solved by the invention can be realized by the following technical scheme.
A complex microbial inoculant for liver protection comprising:
leuconostoc mesenteroides dextran subspecies LZ1 and other acceptable food or pharmaceutical excipients.
Further preferably, the complex microbial inoculum further comprises lactobacillus rhamnosus (lactobacillus rhamnosus) strain CGMCC No. 3002.
The compound microbial inoculum can be prepared into oral liquid, freeze-dried powder, capsules and the like.
The compound microbial inoculum can also be used for preparing health-care food from fermented food.
The food product is preferably fruit.
The invention has the advantages that:
the leuconostoc mesenteroides dextran subspecies LZ1 is separated from the traditional fruit litchi, and the safety of the fruit litchi is ensured. Lactobacillus rhamnosus is also a conventional probiotic. The mixed use has good in-vivo anti-alcohol effect, good liver protection effect and wide application prospect.
Detailed Description
The following examples of the present invention are described in detail, and are only for the purpose of illustrating the present invention and are not to be construed as limiting the present invention.
Specific examples of the present invention are described below. The Leuconostoc mesenteroides dextran subspecies LZ1 and the Lactobacillus rhamnosus strain CGMCC No.3002 used in the invention are obtained by obtaining.
Example 1 in vitro anti-hangover potency assay
1. The strain Leuconostoc mesenteroides dextran subspecies LZ1 and the lactobacillus rhamnosus strain CGMCC No.3002 are activated and cultured according to a conventional method. Adding ethanol, ethanol and MRS culture medium solution into the cultured bacterial liquid, and mixing uniformly, wherein the final concentration of ethanol is 20% and 40% according to v/v. Adjusting the concentration of the bacterial liquid to 10 by using MRS + mixed culture medium with corresponding concentration7cfu/ml. And preparing a group of mixing groups: activating Leuconostoc mesenteroides dextran subspecies LZ1 and Lactobacillus rhamnosus strain CGMCC No.3002, and using MRS + to correspond to the strain according to the concentration of 4:1Adjusting the total concentration of the bacteria liquid to 10 by using the mixed culture medium with the concentration7cfu/ml。
2. Ethanol concentrations of the strain at 15min, 30min and 60min are measured by potassium dichromate concentrated sulfuric acid method, and the in vitro hangover alleviating capacity of different strains is determined, and MRS culture medium without strain is used as blank control. The specific results are shown in tables 1 and 2.
Statistical treatment: statistical analysis was performed using SPSS16.0 and the results of the data were expressed as mean ± standard deviation using the t test between groups.
TABLE 1 ethanol concentration (initial ethanol concentration 20%) determined for different degradation times for each group
Note: t-test, x: p <0.05 (compared to blank control)
TABLE 2 ethanol concentration (initial ethanol concentration 40%) determined for different degradation times for each group
Note: t-test, x: p <0.05 (compared to blank control)
It can be seen that in vitro environment, Leuconostoc mesenteroides dextran subspecies LZ1 has obvious capacity of degrading ethanol, Lactobacillus rhamnosus strain CGMCC No.3002 has no capacity of degrading ethanol when used alone, but the capacity of degrading ethanol is improved when the two strains are used together.
Example 2 in vivo anti-hangover Effect measurement
Healthy ICR male mice were selected as 50 mice, and after 1 week of rearing, the official experiment was started and randomly divided into 5 groups of 10 mice each, and the weights of the mice were not statistically different among the groups. Mice were divided into 5 groups. Pure water or bacterial liquid (0.2ml/25g of dosage) is used for the first intragastric administration of each group, and the concentration configuration method of the bacterial liquid of the 3 rd to 5 th groups (treatment groups) is the same as that of the example 1; half an hour later, mice were given a second intragastric administration with purified water in group 1 and 40% ethanol in water (0.2ml/25g dose) in groups 2-4 as follows:
group 1: purified water + purified water control group (negative control group);
group 2: purified water + 40% ethanol concentration treated group (positive control group);
group 3: a leuconostoc mesenteroides dextran subspecies LZ1 bacterial liquid and 40% ethanol concentration treatment group;
and 4, carrying out: a lactobacillus rhamnosus strain CGMCC No.3002 bacterial liquid and 40% ethanol concentration treatment group;
group 5: mixed bacteria liquid and 40% ethanol concentration treatment group.
Blood is collected from inner canthus of capillary eye twice in the second intragastric lavage (ethanol lavage) for 30min and 2h, and the blood is placed at room temperature for 120min, centrifuged at 2500rpm for 15min to obtain serum, and the alcohol concentration is measured by gas chromatography. Specific results are shown in table 3.
TABLE 3 serum alcohol concentration (mg/dl) after gastric lavage with ethanol
| 30min | 120min | |
| Leuconostoc mesenteroides dextran subspecies LZ1 | 210.62±15.2412 | 70.58±11.9912 |
| Lactobacillus rhamnosus strain CGMCC No.3002 | 321.83±13.441 | 131.91±9.281 |
| LZ1+CGMCC No.3002 | 189.37±10.2312 | 54.54±5.2212 |
| Negative control | 0 | 0 |
| Positive control | 325.71±13.12 | 139.81±10.42 |
Note: t test, l: p <0.05 (compared to negative control); 2: p <0.05 (compare with positive control group)
As a result, it was found that, when Leuconostoc mesenteroides dextran subspecies LZ1 was administered in vivo, there was a statistical difference in serum alcohol concentration (P <0.05) with respect to the positive control group. When lactobacillus rhamnosus strain CGMCC No.3002 is added, the concentration of serum alcohol after gastric lavage is lower, which shows that the synergistic antialcoholic effect is achieved.
ALT kit and AST kit (constructed organism) are adopted to measure ALT and AST activity in serum. The results are shown in Table 4.
TABLE 4 liver function assay in groups of mice after gastric lavage with ethanol
| ALT | ALT | |
| Leuconostoc mesenteroides dextran subspecies LZ1 | 38.11±3.2212 | 79.52±4.2912 |
| Lactobacillus rhamnosus strain CGMCC No.3002 | 45.73±6.721 | 103.50±7.751 |
| LZ1+CGMCC No.3002 | 35.69±3.5912 | 63.86±8.9912 |
| Negative control | 30.60±7.12 | 55.19±8.21 |
| Positive control | 47.26±9.62 | 107.11±10.22 |
Note: t test, l: p <0.05 (compared to negative control); 2: p <0.05 (compare with positive control group)
As a result, ALT and AST can be obviously reduced when compared with the positive group (P <0.05) by the leuconostoc mesenteroides dextran subspecies LZ1, which indicates that the liver function is obviously protected. When lactobacillus rhamnosus strain CGMCC No.3002 is added, the synergistic protection effect is achieved, and ALT and AST are reduced more obviously.
Therefore, a certain damage is caused to the liver by drinking a large amount, and the composite microbial inoculum has the function of preventing the damage of the liver cells.
In conclusion, in the research and practice processes of the team, the leuconostoc mesenteroides dextran subspecies LZ1 is separated from the traditional fruit litchi, and the safety of the litchi is ensured. Lactobacillus rhamnosus is also a conventional probiotic. The mixed use has good in-vivo anti-alcohol effect, good liver protection effect and wide application prospect.
The description of the terms "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
While embodiments of the invention have been shown and described, it will be understood by those of ordinary skill in the art that: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.
Claims (6)
1. A complex microbial inoculant for liver protection comprising:
leuconostoc mesenteroides dextran subspecies LZ1 and other acceptable food or pharmaceutical excipients.
2. The complex microbial agent of claim 1, characterized in that:
the complex microbial inoculum also comprises a Lactobacillus rhamnosus (Lactobacillus rhamnosus) strain CGMCC No. 3002.
3. The complex microbial inoculum of claim 1 or 2, which can be prepared into oral liquid, freeze-dried powder, capsules and the like.
4. The complex microbial inoculant of claim 1 or 2, wherein the complex microbial inoculant is used for fermentation.
5. The use of claim 4, wherein:
can be used for preparing health food from fermented food.
6. The use of claim 5, wherein:
the food is fruit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911418378.2A CN110881663A (en) | 2019-12-31 | 2019-12-31 | Complex microbial inoculant for liver protection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911418378.2A CN110881663A (en) | 2019-12-31 | 2019-12-31 | Complex microbial inoculant for liver protection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110881663A true CN110881663A (en) | 2020-03-17 |
Family
ID=69753464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911418378.2A Withdrawn CN110881663A (en) | 2019-12-31 | 2019-12-31 | Complex microbial inoculant for liver protection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110881663A (en) |
-
2019
- 2019-12-31 CN CN201911418378.2A patent/CN110881663A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109666615B (en) | Probiotic composition and application thereof | |
| CN109628358B (en) | Composite probiotics and application thereof | |
| TWI463986B (en) | New use of lactobacillus plantarum cmu995 strain | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN112244299B (en) | Probiotic composition with function of relieving nonalcoholic fatty liver and preparation method thereof | |
| CN104127443B (en) | Lactobacillus plantarum C88 and panaxan's composition a kind of preparation method | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN109528814B (en) | Microecological preparation of lactobacillus fermented astragalus membranaceus as well as preparation method and application of microecological preparation | |
| CN112999261A (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| WO2022151790A1 (en) | Bifidobacterium longum dietary combination for intervening with chronic nephritis and uremia, and use thereof | |
| CN114432346A (en) | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN111281897B (en) | Complex microbial inoculant for cardiovascular diseases | |
| JP3644500B2 (en) | Method for producing mushroom lactic acid fermented liquid and mushroom lactic acid fermented liquid produced therefrom | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN114287633A (en) | Probiotic composition containing cranberry and application of probiotic composition in resisting helicobacter pylori | |
| JP6301024B2 (en) | Felicaribacterium spp. | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN111867402A (en) | Agaricus campestris composite mycelium composition with liver function improving activity and its preparation method | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| JP2005213211A (en) | Agent for inhibiting increase of blood glucose level | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN110881663A (en) | Complex microbial inoculant for liver protection | |
| CN111269853B (en) | Composite microbial inoculum with liver protection effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200317 |